

# Living with Paroxysmal Nocturnal Hemoglobinuria (PNH)?

The ACCESS-1 Study is a clinical trial comparing the effects of an experimental combination treatment of **pozelimab and cemdisiran**, versus **ravulizumab** treatment in adults with PNH.

The study drugs, **pozelimab and cemdisiran**, may work together to reduce the levels and activity of C5, a protein involved in the destruction of red blood cells in people with PNH.



The study drugs, **pozelimab and cemdisiran**, are given as injections under the skin.\*



Ravulizumab is given by regular infusions into a vein.

If you are an adult with PNH who has not received a type of treatment called a complement inhibitor (such as ravulizumab or eculizumab) or has not received a complement inhibitor in the last 6 months, you may be eligible for this study.

*\*The first dose of pozelimab is given as an infusion.*

For more information about the ACCESS-1 Study, contact \_\_\_\_\_

